The Invisible Enemy of Biopharma: Mycoplasma Detection and Decontamination Services Market Powers Toward USD 310 Million by 2032
Hidden from the naked eye, invisible to routine microscopy, and capable of silently destroying years of research in a matter of days—mycoplasma contamination represents one of the most pervasive and devastating threats to cell-based research and biopharmaceutical manufacturing. These tiny bacteria, lacking cell walls and passing through standard sterilization filters, infect an alarming 15-35% of continuous cell cultures in laboratories worldwide according to industry surveillance data. For biopharma quality control directors, cell therapy manufacturing executives, and research laboratory managers, the mycoplasma detection and decontamination services market represents a critical line of defense where regulatory mandates, scientific integrity, and patient safety converge. This market analysis reveals how the explosive growth of cell and gene therapies—with their absolute requirement for mycoplasma-free cell products—is transforming contamination control from a routine quality check into a multi-million-dollar strategic imperative.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Mycoplasma Detection and Decontamination Services – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Mycoplasma Detection and Decontamination Services market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6045051/mycoplasma-detection-and-decontamination-services
Market Analysis: The Growing Battle Against Cell Culture Contamination
The numbers tell a compelling story of sustained, regulatory-driven growth. The global market for Mycoplasma Detection and Decontamination Services was estimated to be worth USD 232 million in 2025 and is projected to reach USD 310 million, growing at a CAGR of 4.3% from 2026 to 2032. This nearly USD 80 million in absolute value creation reflects the progressive institutionalization of mycoplasma testing as a mandatory quality control checkpoint across academic research, biopharmaceutical manufacturing, and cell therapy production.
Mycoplasma detection and decontamination services detect and eliminate mycoplasma contamination in cell cultures. Mycoplasma contamination is a common problem that can affect the results of cell-based experiments. Detection is typically performed by PCR, ELISA, or other molecular methods, while decontamination involves eliminating contaminants and preventing further problems. The insidious nature of mycoplasma contamination makes it particularly dangerous: unlike bacterial or fungal contamination that visibly clouds culture media, mycoplasma grow silently without obvious signs, altering cellular metabolism, gene expression, and drug response profiles in ways that can completely invalidate experimental conclusions without the researcher’s knowledge.
What drives this market’s sustained expansion? The first and most powerful catalyst is the explosive growth of cell and gene therapy manufacturing. Unlike traditional small-molecule drugs where terminal sterilization eliminates contamination concerns, autologous and allogeneic cell therapies involve living cells infused directly into patients—making mycoplasma contamination a direct patient safety threat. The FDA requires rigorous mycoplasma testing at multiple stages of cell therapy manufacturing: donor screening, cell bank characterization, in-process monitoring, and final product release. Each CAR-T cell therapy batch, for example, undergoes 2-4 separate mycoplasma tests during the 2-4 week manufacturing process, creating recurring demand that scales with the expanding cell therapy pipeline. The Alliance for Regenerative Medicine reported that over 2,200 active cell and gene therapy clinical trials were underway globally in 2025, with each program generating sustained mycoplasma testing demand throughout its development lifecycle.
The second growth engine is the pharmaceutical industry’s increasing reliance on biologic drug modalities manufactured in mammalian cell culture systems. Monoclonal antibodies, recombinant proteins, and viral vectors—which collectively represented over USD 280 billion in global sales in 2025—all require mycoplasma testing per regulatory requirements in both the US Pharmacopeia Chapter <63> and European Pharmacopoeia Chapter 2.6.7. Charles River Laboratories’ 2025 annual report highlighted that its biologics testing division, which includes mycoplasma detection services, achieved 15% year-over-year revenue growth, with cell and gene therapy applications representing the fastest-growing segment. The company’s March 2026 expansion of its mycoplasma testing capacity at its Memphis facility, adding 35% additional throughput, signals confidence in sustained demand growth.
Industry Outlook: The Technology Arsenal for Mycoplasma Detection
The Mycoplasma Detection and Decontamination Services market segments by type into PCR-based Mycoplasma Detection, Enzyme Detection, Fluorescent Staining, and Other methods, reflecting the multi-tiered technology landscape for contamination control. PCR-based detection has emerged as the dominant methodology, accounting for approximately 58% of testing volume according to industry estimates. The technology’s advantages are compelling: turnaround times of 24-48 hours compared to 28 days for traditional culture-based methods, sensitivity capable of detecting fewer than 10 mycoplasma genome copies per reaction, and the ability to detect non-cultivable mycoplasma species that would be missed by culture-based approaches.
Enzyme detection methods, based on mycoplasma-specific enzyme activity producing bioluminescent signals, offer the fastest turnaround time—as little as 20-30 minutes—making them ideal for in-process testing during cell therapy manufacturing where time is critical. Thermo Fisher Scientific’s 2025 annual report highlighted that its MycoAlert mycoplasma detection system achieved 18% year-over-year reagent revenue growth, with cell therapy manufacturing representing the primary growth driver. Fluorescent staining, using DNA-binding dyes such as Hoechst 33258 to visualize mycoplasma DNA in cultured cells, remains an important complementary method, particularly for academic laboratories where the low per-test cost—approximately USD 5-15—makes it accessible for routine surveillance.
Development Trends: The Cell Therapy Quality Revolution
Several powerful development trends are reshaping this industry landscape. The FDA’s February 2026 final guidance on potency assurance for cell and gene therapy products explicitly identified mycoplasma testing as a critical quality attribute requiring validated, sensitive detection methods throughout the manufacturing process. This regulatory clarity is driving adoption of rapid PCR-based methods that enable real-time contamination monitoring, replacing the traditional 28-day culture method that was incompatible with the short shelf life of autologous cell therapy products.
The second transformative trend is the integration of mycoplasma testing into comprehensive cell line quality assessment packages. Rather than purchasing standalone mycoplasma testing, pharmaceutical clients increasingly prefer integrated quality control services that combine mycoplasma detection with sterility testing, viral safety testing, and cell line authentication. Applied Biological Materials Inc.’s 2025 annual report highlighted that its integrated quality control service packages achieved 22% year-over-year revenue growth.
Competitive Landscape and Future Outlook
Key market participants include Applied Biological Materials Inc. (abm), Thermo Fisher Scientific, Creative Bioarray, BaseClear, QED Bioscience Inc., QTCC, Charles River Laboratories, Minerva Biolabs, InvivoGen, and R&D Systems. The competitive landscape features global contract research organizations, specialized contamination control companies, and life science technology providers. Charles River Laboratories leverages its comprehensive biologics testing portfolio to serve pharmaceutical clients requiring multi-analyte quality control solutions. Thermo Fisher Scientific’s combination of MycoAlert detection reagents and rapid PCR platforms positions it across both rapid enzyme-based and molecular testing segments.
The mycoplasma detection and decontamination services market’s trajectory toward USD 310 million by 2032 at a 4.3% CAGR reflects sustained, regulatory-driven growth in a specialized life sciences quality control segment. Stakeholders who invest in rapid molecular detection methods, integrated testing packages, and regulatory-compliant documentation systems will capture disproportionate value as cell and gene therapy manufacturing continues its explosive expansion and regulatory expectations for contamination control continue to strengthen.
Segment by Type
PCR-based Mycoplasma Detection
Enzyme Detection
Fluorescent Staining
Other
Segment by Application
Biomedicine
Cell Therapy and Genetic Engineering
Other
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
